GSK completes study for COPD treatment

By Benjamin Chiou

Date: Friday 24 Aug 2012

Pharmaceuticals giant GlaxoSmithKline announced on Friday afternoon that it has completed, along with partner Theravance, the phase III programme of a 52-week safety study for its UMEC/VI medicine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

The 6,000-patient study, along with other recently completed studies, “supports GSK's plans to commence global regulatory submissions for UMEC/VI from the end of 2012,” the firm said.

UMEC/VI is one of several late-stage assets in Glaxo’s respiratory development portfolio which have not yet been approved anywhere in the world.

Shares were trading 0.69% higher at 1,461p before the close.

BC

« Go back to news channel

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE